AYTU BioPharma
AYTU
21 hedge funds and large institutions have $2.73M invested in AYTU BioPharma in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
125% more capital invested
Capital invested by funds: $1.21M → $2.73M (+$1.51M)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
29.79% more ownership
Funds ownership: 15.3% → 45.09% (+30%)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.6M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$927K |
| 3 |
Renaissance Technologies
New York
|
+$15.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.7K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$168K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$106K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$35K |
| 4 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
-$10.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.84K |
AYTU Hedge Fund Activity: Q2 2023 in Review
21 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q2 2023, worth a combined $2.73M — up 125% from $1.21M a quarter earlier.
Fund positioning in AYTU was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 4 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $1.6M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $168K sold.
- 21 institutional investors held AYTU BioPharma (AYTU) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $2.73M of AYTU BioPharma stock for Q2 2023, up 125% quarter-over-quarter.
- 3 funds opened new AYTU BioPharma positions in Q2 2023 and 3 closed out, a net change of 0 holders.
- The largest AYTU BioPharma buyer in Q2 2023 was Nantahala Capital Management, an estimated $1.6M added.
- The largest AYTU BioPharma seller in Q2 2023 was Alyeska Investment Group, an estimated $168K sold.
Based on aggregated 13F filings for Q2 2023.